https://mindmedicinelaw.com/briefing/fda-eases-510-k-rules-for-toxicology-devices-impacts-for-psychedelic-testing-20261006-47248The Psychedelic Journalen2026-10-06T15:06:08.815434+00:00FDA Eases 510(k) Rules for Toxicology Devices—Impacts for Psychedelic Testingfda, 510(k) exemption, clinical toxicology, psychedelic research, device regulation, clinical trials, assay development, policy change, laboratory testing, public healthhttps://mindmedicinelaw.com/briefing/fda-requests-input-on-ibogaine-trial-design-for-oud-and-ptsd-20261006-47220The Psychedelic Journalen2026-10-06T15:05:36.846485+00:00FDA Requests Input on Ibogaine Trial Design for OUD and PTSDfda, ibogaine, clinical trial design, opioid use disorder, ptsd, psychedelic regulation, safety monitoring, public docket, federal research, policyhttps://mindmedicinelaw.com/briefing/psilocybin-social-cognition-and-aud-trial-endpoints-under-scrutiny-20261005-47048The Psychedelic Journalen2026-10-05T15:06:18.994476+00:00Psilocybin, Social Cognition, and AUD: Trial Endpoints Under Scrutinypsilocybin, alcohol use disorder, social cognition, clinical trial endpoints, FDA, neuropsychiatric outcomes, psychedelic research, regulatory science, clinical trial designhttps://mindmedicinelaw.com/briefing/telehealth-ketamine-elevate-holistics-at-home-launch-and-us-policy-gaps-20261005-47049The Psychedelic Journalen2026-10-05T15:06:00.999066+00:00Telehealth Ketamine: Elevate Holistics’ At-Home Launch and US Policy Gapstelehealth ketamine, at-home psychedelic therapy, elevate holistics, dea telemedicine policy, us ketamine regulation, psychedelic telemedicine, clinical oversight, controlled substances, mental health accesshttps://mindmedicinelaw.com/briefing/fda-requests-public-comment-on-ibogaine-research-pathways-20261005-47047The Psychedelic Journalen2026-10-05T15:05:30.146566+00:00FDA Requests Public Comment on Ibogaine Research Pathwaysfda, ibogaine, psychedelic research, public comment, clinical trials, regulatory policy, substance use disorder, schedule i, cardiac risk, drug developmenthttps://mindmedicinelaw.com/briefing/fda-sets-approval-pathway-for-psilocybin-and-lsd-therapies-20261004-46886The Psychedelic Journalen2026-10-04T22:03:28.759323+00:00FDA Sets Approval Pathway for Psilocybin and LSD Therapiesfda, psilocybin, lsd, psychedelic approval, drug policy, breakthrough therapy, clinical trials, controlled substances act, risk management, digital health toolshttps://mindmedicinelaw.com/briefing/esketamine-vs-off-label-ketamine-u-s-regulatory-divide-deepens-20261003-47308The Psychedelic Journalen2026-10-06T15:06:24.149135+00:00Esketamine vs. Off-Label Ketamine: U.S. Regulatory Divide Deepensesketamine, ketamine clinics, off-label use, fda approval, psychedelic policy, insurance coverage, legal risk, rems program, clinical guidelines, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/siadh-serotonergic-toxicity-and-hyponatremia-clinical-implications-for-antidepre-20261003-46936The Psychedelic Journalen2026-10-05T15:06:39.933261+00:00SIADH, Serotonergic Toxicity, and Hyponatremia: Clinical Implications for Antidepressants and Psychedelicssiadh, serotonergic toxicity, hyponatremia, antidepressants, psilocybin, ketamine, clinical trial safety, adverse drug reactions, serotonin syndrome, electrolyte monitoringhttps://mindmedicinelaw.com/briefing/sex-typical-brain-connectivity-mood-disorders-and-neurodegeneration-implications-20261002-46982The Psychedelic Journalen2026-10-05T15:08:11.649208+00:00Sex-Typical Brain Connectivity, Mood Disorders, and Neurodegeneration: Implications for Psychiatric Researchsex-typical brain connectivity, mood disorders, neurodegeneration, biomarkers, personalized medicine, psychedelic trials, transcriptomics, clinical trial design, sex differences, functional connectivityhttps://mindmedicinelaw.com/briefing/il-6-antagonist-proof-of-concept-for-depression-jama-psychiatry-2026-20261002-46987The Psychedelic Journalen2026-10-05T15:07:49.800929+00:00IL-6 Antagonist Proof-of-Concept for Depression: JAMA Psychiatry 2026il-6 antagonist, tocilizumab, depression, inflammation, immunopsychopharmacology, clinical trial, jama psychiatry, biomarker stratification, psychedelic research, antidepressant adjuncthttps://mindmedicinelaw.com/briefing/regulatory-complexities-in-u-s-psychedelics-policy-amid-rapid-drug-development-20261002-46971The Psychedelic Journalen2026-10-05T15:07:31.138447+00:00Regulatory Complexities in U.S. Psychedelics Policy Amid Rapid Drug Developmentpsychedelic regulation, federal vs state policy, FDA approval pathways, psilocybin law, MDMA clinical trials, compliance risks, public health policy, drug scheduling, market uncertaintyhttps://mindmedicinelaw.com/briefing/semaglutide-lowers-heavy-drinking-in-phase-2-aud-trial-20261002-46970The Psychedelic Journalen2026-10-05T15:07:12.890333+00:00Semaglutide Lowers Heavy Drinking in Phase 2 AUD Trialsemaglutide, glp-1 agonists, alcohol use disorder, phase 2 trial, heavy drinking days, addiction treatment, psychedelic therapy, regulatory benchmarks, clinical trial designhttps://mindmedicinelaw.com/briefing/high-resolution-mapping-of-human-habenula-illuminates-depression-links-20261002-46985The Psychedelic Journalen2026-10-05T15:06:56.476640+00:00High-Resolution Mapping of Human Habenula Illuminates Depression Linkshabenula, spatial transcriptomics, multi-omic sequencing, depression, psychedelic research, biomarker development, clinical trial design, genetic risk, brain circuits, addictionhttps://mindmedicinelaw.com/briefing/ect-alters-brain-dynamics-in-trd-mechanistic-clues-for-psychedelic-therapies-20261001-46995The Psychedelic Journalen2026-10-05T15:08:30.579229+00:00ECT Alters Brain Dynamics in TRD: Mechanistic Clues for Psychedelic Therapieselectroconvulsive therapy, treatment-resistant depression, brain network dynamics, hidden markov model, neurotransmitter systems, psychedelic therapy, clinical trials, mechanistic insights, fMRI, neuromodulationhttps://mindmedicinelaw.com/briefing/psychedelic-compound-reduces-chemotherapy-induced-neuropathy-new-evidence-20260929-47305The Psychedelic Journalen2026-10-06T15:05:53.371089+00:00Psychedelic Compound Reduces Chemotherapy-Induced Neuropathy: New Evidencepsychedelic research, chemotherapy-induced neuropathy, oncology supportive care, neuroprotection, clinical trials, FDA regulation, psychedelic compounds, cancer pain management, neuroinflammation, public health policyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-spatial-working-memory-implications-for-clinical-trials-and-20260928-47303The Psychedelic Journalen2026-10-06T15:06:37.074564+00:00Ketamine’s Impact on Spatial Working Memory: Implications for Clinical Trials and Policyketamine, spatial working memory, cognitive effects, clinical trial design, neuroimaging, NMDA receptor, psychiatric safety, regulatory policy, cognitive risk, psychedelic research